NYSE - Nasdaq Real Time Price USD

Ginkgo Bioworks Holdings, Inc. (DNA)

Compare
9.44 -0.89 (-8.62%)
At close: December 13 at 4:00:02 PM EST
9.31 -0.13 (-1.38%)
After hours: December 13 at 7:46:47 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
217,107.00
251,455.00
477,706.00
313,837.00
76,657.00
Cost of Revenue
41,537.00
54,005.00
204,216.00
129,690.00
15,611.00
Gross Profit
175,570.00
197,450.00
273,490.00
184,147.00
61,046.00
Operating Expense
742,809.00
965,646.00
2,482,442.00
2,012,614.00
198,073.00
Operating Income
-567,239.00
-768,196.00
-2,208,952.00
-1,828,467.00
-137,027.00
Net Non Operating Interest Income Expense
44,485.00
57,124.00
20,156.00
-1,536.00
197.00
Other Income Expense
-128,787.00
-181,868.00
67,397.00
-8,119.00
11,996.00
Pretax Income
-651,541.00
-892,940.00
-2,121,399.00
-1,838,122.00
-124,834.00
Tax Provision
-352.00
-71.00
-15,027.00
-1,480.00
1,889.00
Net Income Common Stockholders
-651,520.00
-892,869.00
-2,108,072.00
-1,888,662.00
-126,609.00
Diluted NI Available to Com Stockholders
-651,520.00
-892,869.00
-2,108,072.00
-1,888,662.00
-126,609.00
Basic EPS
-12.89
-18.40
-50.00
-54.00
-0.09
Diluted EPS
-12.89
-18.40
-50.00
-55.60
-0.09
Basic Average Shares
50,796.00
48,610.50
41,976.54
33,996.22
1,485,061.24
Diluted Average Shares
50,800.50
48,610.50
41,995.97
34,009.33
1,485,061.24
Total Operating Income as Reported
-634,268.00
-864,406.00
-2,208,952.00
-1,828,467.00
-137,027.00
Total Expenses
784,346.00
1,019,651.00
2,686,658.00
2,142,304.00
213,684.00
Net Income from Continuing & Discontinued Operation
-651,189.00
-892,869.00
-2,104,929.00
-1,830,047.00
-126,609.00
Normalized Income
-520,677.55
-704,512.98
-2,207,728.33
-1,900,874.10
-129,932.69
Interest Income
44,578.00
57,217.00
20,262.00
837.00
2,582.00
Interest Expense
--
93.00
106.00
2,373.00
2,385.00
Net Interest Income
44,485.00
57,124.00
20,156.00
-1,536.00
197.00
EBIT
-691,890.00
-892,847.00
-2,121,293.00
-1,835,749.00
-122,449.00
EBITDA
-630,638.00
-821,293.00
-2,076,870.00
-1,806,673.00
-108,585.00
Reconciled Cost of Revenue
41,537.00
54,005.00
204,216.00
129,690.00
15,611.00
Reconciled Depreciation
61,252.00
71,554.00
44,423.00
29,076.00
13,864.00
Net Income from Continuing Operation Net Minority Interest
-651,189.00
-892,869.00
-2,104,929.00
-1,830,047.00
-126,609.00
Total Unusual Items Excluding Goodwill
-130,582.00
-188,371.00
103,524.00
70,898.00
4,553.00
Total Unusual Items
-130,582.00
-188,371.00
103,524.00
70,898.00
4,553.00
Normalized EBITDA
-500,056.00
-632,922.00
-2,180,394.00
-1,877,571.00
-113,138.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-70.55
-14.98
724.67
70.90
1,229.31
12/31/2020 - 4/19/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BEAM Beam Therapeutics Inc.
27.93
-0.46%
 
NTLA Intellia Therapeutics, Inc.
12.90
-4.87%
 
CRSP CRISPR Therapeutics AG
43.78
-3.57%
 
EDIT Editas Medicine, Inc.
1.4400
-23.81%
 
RXRX Recursion Pharmaceuticals, Inc.
6.95
-0.43%
 
ABCL AbCellera Biologics Inc.
2.8100
-4.75%
 
BLUE bluebird bio, Inc.
6.34
-16.58%
 
VERV Verve Therapeutics, Inc.
5.71
-8.35%
 
IBRX ImmunityBio, Inc.
2.8700
-5.59%
 
ABSI Absci Corporation
3.6950
+0.41%